PAX8

A sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy

Yue Wang, Yiying Wang, Jie Li, Zeng Yuan, Bingbing Yuan, Tingguo Zhang, Janiel M. Cragun, Beihua Kong, Wenxin Zheng

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy. Methods. Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n = 96), metastatic cancers (n = 22), and benign controls (n = 50). Results: Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79%) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21%) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n = 4) and the metastasis from gastrointestinal tract (n = 17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n = 4) and endometriosis (n = 1), 25 PAX8-/Calretinin + cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia. Conclusions: PAX8 identifies all Müllerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.

Original languageEnglish (US)
Article number60
JournalJournal of Hematology and Oncology
Volume6
Issue number1
DOIs
StatePublished - Sep 30 2013

Fingerprint

Calbindin 2
Ovarian Neoplasms
Drug Therapy
Cell Biology
Epithelium
Pelvic Neoplasms
Neoplasm Metastasis
Neoplasms
Endometriosis
Tumor Biomarkers
Renal Cell Carcinoma
Ascites
Gastrointestinal Tract
Blood Cells
Adenocarcinoma
Breast
Biomarkers
Epithelial Cells
Pathology
Carcinoma

Keywords

  • Ascitic fluid
  • Marker
  • Neoadjuvant chemotherapy
  • Origin
  • Ovarian cancer
  • PAX8

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology

Cite this

PAX8 : A sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy. / Wang, Yue; Wang, Yiying; Li, Jie; Yuan, Zeng; Yuan, Bingbing; Zhang, Tingguo; Cragun, Janiel M.; Kong, Beihua; Zheng, Wenxin.

In: Journal of Hematology and Oncology, Vol. 6, No. 1, 60, 30.09.2013.

Research output: Contribution to journalArticle

Wang, Yue ; Wang, Yiying ; Li, Jie ; Yuan, Zeng ; Yuan, Bingbing ; Zhang, Tingguo ; Cragun, Janiel M. ; Kong, Beihua ; Zheng, Wenxin. / PAX8 : A sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy. In: Journal of Hematology and Oncology. 2013 ; Vol. 6, No. 1.
@article{ca9ab1439e0342f9a30472b450fae864,
title = "PAX8: A sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy",
abstract = "Background: Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy. Methods. Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n = 96), metastatic cancers (n = 22), and benign controls (n = 50). Results: Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79{\%}) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21{\%}) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n = 4) and the metastasis from gastrointestinal tract (n = 17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n = 4) and endometriosis (n = 1), 25 PAX8-/Calretinin + cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia. Conclusions: PAX8 identifies all M{\"u}llerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.",
keywords = "Ascitic fluid, Marker, Neoadjuvant chemotherapy, Origin, Ovarian cancer, PAX8",
author = "Yue Wang and Yiying Wang and Jie Li and Zeng Yuan and Bingbing Yuan and Tingguo Zhang and Cragun, {Janiel M.} and Beihua Kong and Wenxin Zheng",
year = "2013",
month = "9",
day = "30",
doi = "10.1186/1756-8722-6-60",
language = "English (US)",
volume = "6",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - PAX8

T2 - A sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy

AU - Wang, Yue

AU - Wang, Yiying

AU - Li, Jie

AU - Yuan, Zeng

AU - Yuan, Bingbing

AU - Zhang, Tingguo

AU - Cragun, Janiel M.

AU - Kong, Beihua

AU - Zheng, Wenxin

PY - 2013/9/30

Y1 - 2013/9/30

N2 - Background: Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy. Methods. Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n = 96), metastatic cancers (n = 22), and benign controls (n = 50). Results: Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79%) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21%) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n = 4) and the metastasis from gastrointestinal tract (n = 17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n = 4) and endometriosis (n = 1), 25 PAX8-/Calretinin + cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia. Conclusions: PAX8 identifies all Müllerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.

AB - Background: Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy. Methods. Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n = 96), metastatic cancers (n = 22), and benign controls (n = 50). Results: Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79%) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21%) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n = 4) and the metastasis from gastrointestinal tract (n = 17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n = 4) and endometriosis (n = 1), 25 PAX8-/Calretinin + cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia. Conclusions: PAX8 identifies all Müllerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.

KW - Ascitic fluid

KW - Marker

KW - Neoadjuvant chemotherapy

KW - Origin

KW - Ovarian cancer

KW - PAX8

UR - http://www.scopus.com/inward/record.url?scp=84884547681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884547681&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-6-60

DO - 10.1186/1756-8722-6-60

M3 - Article

VL - 6

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 60

ER -